Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 5/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20154582 | 0.84 | RET (0.47) | RETDPP4DPP7DPP8CACNA1B | |
| SCHEMBL20069729 | 0.83 | RET (0.46) | RETDPP4DPP7DPP8CACNA1B | |
| SCHEMBL20069727 | 0.82 | RET (0.44) | RETDPP4DPP7DPP8CACNA1B | |
| SCHEMBL22030577 | 0.71 | RET (0.47) | RETDPP4DPP7DPP8DPP9 | |
| SCHEMBL20069728 | 0.70 | RET (0.48) | RETDPP4DPP7DPP8DPP9 | |
| SCHEMBL20152348 | 0.68 | RET (0.45) | RETDPP4DPP7DPP8DPP9 | |
| SCHEMBL20071290 | 0.68 | RET (0.42) | RETDPP4DPP7DPP8DPP9 | |
| SCHEMBL21158895 | 0.68 | RET (0.45) | RETDPP4DPP7DPP8DPP9 | |
| SCHEMBL22030851 | 0.67 | RET (0.44) | RETDPP4DPP7DPP8DPP9 | |
| SCHEMBL21159093 | 0.66 | CHRM1 (0.52) | CACNA1BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | RET 1/4885DPP4 1948/4885DPP7 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.